Current Use and Impact of Pulmonary Artery Catheters on the Short-Term Outcomes in Patients With Cardiogenic Shock Treated With an Impella: Findings From the Japan Registry for Percutaneous Ventricular Assist Device (J-PVAD)
Authors' conclusion
The J-PVAD findings indicated that PAC use did not have a significant impact on the short-term outcomes in CS patients undergoing Impella support.
Study context
- Population
- Patients with cardiogenic shock treated with an Impella (2.5, CP or 5.0), cardiac ICUs in Japan, J-PVAD registry, January 2020–December 2021Cardiogenic shock (CS) patients of 3112 enrolled
- Participants
- 2,063 patients
- Exposure
- PAC use vs no PAC use
- Pulmonary artery catheters (PACs)n = 1,358
- Outcome
- 30-day mortality
- Follow-up
- 30 days
Methodological detailsregistry
- Registry
Main finding
As reported in the abstract
- 30-day mortality did not significantly differ according to PAC use
Observational data: associations, not effects.
Secondary outcomes
Hemolysis, AKI, sepsis, major bleeding unrelated to the Impella, ventricular arrhythmias · within 30 days
- Did not significantly differ according to PAC use
Venoarterial extracorporeal membrane oxygenation (VA-ECMO) use
- Significantly higher with PACs than without
30-day mortality and hemolysis (VA-ECMO subgroup)
- Univariately lower with PACs
- Univariate
Original publication
Current Use and Impact of Pulmonary Artery Catheters on the Short-Term Outcomes in Patients With Cardiogenic Shock Treated With an Impella: Findings From the Japan Registry for Percutaneous Ventricular Assist Device (J-PVAD). Crit Care Med. Published 9 February 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →